KI in Drug Discovery 2021: Spieler, Technologien und Anwendungen: IDTechEx

AI cuts drug discovery timelines from 5+ years to a few months.

KI in Drug Discovery 2021: Spieler, Technologien und Anwendungen

Künstliche Intelligenz (maschinelles Lernen und Deep Learning) in den Bereichen virtuelles Screening, De-novo-Arzneimitteldesign, Lead-Optimierung und chemische Syntheseplanung.


Show All Description Contents, Table & Figures List Pricing Related Content
The development of pharmaceutical drugs is a long and costly process. Companies in the pharmaceutical and biotechnology industries typically spend more than $1 billion to bring a drug to market, in a process that often lasts over 10-15 years. Moreover, the drug development process is very risky - up to 90% of drug candidates are eventually dropped during the process due to issues such as safety and efficacy, resulting in massive losses for companies. Any technology that can contribute significantly to solving any of these three pain points of the drug development process will quickly grow into a multibillion-dollar industry.
 
One such technology that has emerged over the past few years is the use of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL) algorithms, to improve the drug discovery process. In this early stage of the drug development process, compounds of interest are identified and optimized to have drug-like properties before they are tested in animals, and later, humans. While computers have been used in aiding pharmaceutical R&D for many decades and even AI itself has been applied for more than 10 years, it has only recently started to gather momentum. Case in point - over 80% of funding for AI in drug discovery has been raised in the past 3 years, with investment over 2020, during the height of the COVID-19 pandemic, more than that of 2018 and 2019 combined.
 
Why apply AI in drug discovery?
Companies commercializing AI drug discovery platforms and AI-discovered drugs have shown that the use of algorithms can accelerate a multi-year process to a matter of months. This drastic decrease in development time along with the reduction of the number of compounds that need to be synthesized for laboratory testing, allows for significant cost savings, addressing two core issues of pharmaceutical R&D. While AI drug discovery companies have not necessarily proven that their technologies can bring a drug to market (i.e., successfully pass clinical trials) with higher rates of success than traditional drug discovery methods, the accelerated timelines and potential for cost savings are compelling enough for pharmaceutical companies across the world to either invest internally to develop their own AI capabilities, and to partner up with AI companies in billion-dollar deals.
 
Structure-based virtual screening identifies molecules (ligands) that are predicted to bind to a biological structure (target). Structure-based virtual screening is the leading form of AI in drug discovery being funded today. Source: IDTechEx Research
How is AI applied in drug discovery?
In this report, IDTechEx have focused on the areas of virtual screening and de novo drug discovery as two aspects of drug discovery in which significant activity is occurring. Specific applications such as structure-based virtual screening are receiving significant attention, but it is not yet fully clear which aspect of AI in drug discovery will have the most impact in the future. While structure-based virtual screening is enabled by ready availability of structural data on which to apply AI algorithms, the complexity of biological systems means that structure and fit of compounds do not indicate a compound's safety and efficacy as a drug. Technologies such as phenotypic virtual screening and de novo drug discovery may hold more promise for first-in-class and even multi-target drugs, and all aspects will be supported by the application of AI in the prediction and optimization of a compound's properties.
 
 
What's in the report?
This report covers four aspects of the drug discovery process:
  • Virtual screening, including structure-based virtual screening, ligand-based virtual screening, and phenotypic virtual screening
  • De novo drug design
  • Lead optimization (predicting and optimizing compound properties)
  • Chemical synthesis planning
 
Within each aspect of the drug discovery process discussed, IDTechEx provides:
  • Key players
  • Funding (including breakdown by application and drug type)
  • Technologies
  • Company profiles (including interviews)
  • Progress of candidates to market
  • Software capabilities
  • Technology readiness
Analyst access from IDTechEx
All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.
Further information
If you have any questions about this report, please do not hesitate to contact our report team at research@IDTechEx.com or call one of our sales managers:

AMERICAS (USA): +1 617 577 7890
ASIA (Japan): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
Table of Contents
1.EXECUTIVE SUMMARY
1.1.Report Scope
1.2.Report Scope: Drug Discovery
1.3.Challenges in the Drug Discovery Process
1.4.AI in Drug Discovery: Why Now?
1.5.Drivers & Constraints of AI in Drug Discovery
1.6.AI in Virtual Screening
1.7.AI in Virtual Screening: Key Players
1.8.AI in Virtual Screening: Conclusions
1.9.AI in De Novo Drug Design
1.10.AI in De Novo Drug Design: Key players
1.11.AI in De Novo Drug Design: Conclusions
1.12.AI in Lead Optimization
1.13.AI in Chemical Synthesis Planning
1.14.Funding in AI in Drug Discovery
1.15.AI in Drug Discovery: Business Models
1.16.AI in Drug Discovery Market Landscape: By Geography
1.17.AI in Drug Discovery Market Landscape: By Application
1.18.AI in Drug Discovery: Market Outlook
1.19.Conclusions
2.INTRODUCTION
2.1.Report Scope
2.2.The Drug Development Process
2.3.Report Scope: Drug Discovery
2.4.Key Terminology: Targets and Ligands
2.5.Targets and Ligands: Lock and Key Analogy
2.6.Challenges in the Drug Discovery Process
2.7.Drug Discovery is Expensive
2.8.History of AI in Drug Discovery
2.9.AI in Drug Discovery: Why Now?
2.10.Benefits of AI in Drug Discovery
2.11.Drivers & Constraints of AI in Drug Discovery
3.AI IN DRUG DISCOVERY
3.1.1.What is Artificial Intelligence?
3.1.2.AI, ML & DL in Drug Discovery
3.1.3.AI Methods in Drug Discovery
3.1.4.Applicability and Predictive Capabilities of Key AI Algorithms
3.1.5.Constructing an AI Model: Which Algorithms to Use?
3.1.6.How are Compound Structures Encoded into an AI Model?
3.1.7.Molecular Fingerprints
3.1.8.Simplified Molecular Input Line Entry Specification (SMILES)
3.2.AI in Virtual Screening
3.2.1.AI in Virtual Screening
3.2.2.AI in Virtual Screening: Key Players
3.2.3.AI in Virtual Screening: Funding
3.2.4.AI in Virtual Screening: By Application and Drug Type
3.2.5.Structure-Based Virtual Screening
3.2.6.Recursion Pharmaceuticals
3.2.7.Atomwise
3.2.8.Micar Innovation
3.2.9.TwoXAR
3.2.10.Ligand-Based Virtual Screening
3.2.11.Tencent
3.2.12.Phenotypic Virtual Screening
3.2.13.e-Therapeutics
3.2.14.AI in Virtual Screening: Progress from Lab to Bedside
3.2.15.AI for Virtual Screening: Clinical Trials
3.2.16.AI for Virtual Screening: Partnerships
3.2.17.AI in Virtual Screening: Software Capabilities
3.2.18.AI in Virtual Screening: Technology Readiness
3.2.19.AI in Virtual Screening: Conclusions
3.3.Phenotypic Screening: AI for Cell Sorting and Classification
3.3.1.Image Recognition AI
3.3.2.Classification of Phenotypic HTS Results
3.4.AI in De Novo Drug Design
3.4.1.AI in De Novo Drug Design
3.4.2.AI in De Novo Drug Design: Key players
3.4.3.AI in De Novo Drug Design: Funding
3.4.4.AI in De Novo Drug Design: By Drug Type
3.4.5.How does AI-driven De Novo Drug Design Work?
3.4.6.DMTA Cycles Must be Reduced
3.4.7.How does AI-driven De Novo Drug Design Work?
3.4.8.IBM Research Zurich
3.4.9.Insilico Medicine
3.4.10.Exscientia
3.4.11.CaroCure
3.4.12.Aqemia
3.4.13.GlamorousAI
3.4.14.AstraZeneca
3.4.15.Arzeda
3.4.16.BenevolentAI
3.4.17.AI in De Novo Drug Design: Partnerships
3.4.18.AI in De Novo Drug Design: Progress from Lab to Bedside
3.4.19.AI in De Novo Drug Design: Software Capabilities
3.4.20.AI in De Novo Drug Design: Software Capabilities
3.4.21.AI in De Novo Drug Design: Technology Readiness
3.4.22.AI in De Novo Drug Design: Conclusions
3.5.AI in Lead Optimization
3.5.1.AI in Lead Optimization
3.5.2.History of Lead Optimization
3.5.3.Key Properties and AI Algorithms
3.5.4.Predictive Capabilities of Key AI Algorithms
3.5.5.AI in Lead Optimisation: Process
3.5.6.Quantitative Structure-Activity Relationship Models
3.5.7.Intellegens
3.5.8.PEACCEL
3.5.9.ProteinQure
3.5.10.Iktos
3.5.11.Molomics
3.5.12.Denovicon Therapeutics
3.5.13.XtalPi
3.5.14.Peptone
3.5.15.GlaxoSmithKline
3.5.16.AI in Lead Optimization: Software Capabilities
3.5.17.AI in Lead Optimization: Technology Readiness
3.5.18.AI in Lead Optimization: Conclusions
3.5.19.AI in Lead Optimization: Challenges
3.6.AI in Chemical Synthesis Planning
3.6.1.Chemical Synthesis Planning
3.6.2.Retrosynthesis Pathway Prediction
3.6.3.Computer-Aided Retrosynthesis
3.6.4.AI in Chemical Synthesis Planning
3.6.5.AI in Chemical Synthesis Planning: Software Architecture
3.6.6.AI in Chemical Synthesis Planning: Key Players
3.6.7.Merck KGaA
3.6.8.Iktos
3.6.9.PostEra
3.6.10.Molecule.one
3.6.11.DeepMatter
3.6.12.University of Glasgow
3.6.13.AI in Chemical Synthesis Planning: Partnerships
3.6.14.AI in Chemical Synthesis Planning: Software Capabilities
3.6.15.AI in Chemical Synthesis Planning: Technology Readiness
3.6.16.AI in Chemical Synthesis Planning: Conclusions & Outlook
4.MARKET LANDSCAPE
4.1.Overview
4.2.Funding in AI in Drug Discovery
4.3.AI in Drug Discovery: Business Models
4.4.Collaborations Between Big Pharma and AI Companies
4.5.AI in Drug Discovery Market Landscape: By Geography
4.6.AI in Drug Discovery Market Landscape: By Application
4.7.AI in Drug Discovery Market Landscape: By Drug Type
4.8.AI in Drug Discovery Market Landscape: 2010-2020
4.9.AI in Drug Discovery: Market Outlook
5.OUTLOOK
5.1.AI-Driven Automation
5.2.Is Deep Learning Suitable for Drug Discovery?
5.3.Polypharmacology and Multi-Target Drugs
5.4.Data Availability and Data Quality
5.5.Other challenges facing drug discovery AI companies
5.6.Final Thoughts
5.7.Company profiles
 

Ordering Information

KI in Drug Discovery 2021: Spieler, Technologien und Anwendungen

£$¥
Electronic (1-5 users)
£4,650.00
Electronic (6-10 users)
£6,750.00
Electronic and 1 Hardcopy (1-5 users)
£5,050.00
Electronic and 1 Hardcopy (6-10 users)
£7,150.00
Electronic (1-5 users)
€5,250.00
Electronic (6-10 users)
€7,450.00
Electronic and 1 Hardcopy (1-5 users)
€5,700.00
Electronic and 1 Hardcopy (6-10 users)
€7,900.00
Electronic (1-5 users)
$5,995.00
Electronic (6-10 users)
$8,495.00
Electronic and 1 Hardcopy (1-5 users)
$6,495.00
Electronic and 1 Hardcopy (6-10 users)
$8,995.00
Electronic (1-5 users)
¥628,000
Electronic (6-10 users)
¥884,000
Electronic and 1 Hardcopy (1-5 users)
¥678,000
Electronic and 1 Hardcopy (6-10 users)
¥934,000
Click here to enquire about additional licenses.
If you are a reseller/distributor please contact us before ordering.
お問合せ、見積および請求書が必要な方はm.murakoshi@idtechex.com までご連絡ください。

Subscription Enquiry